Fmk is an irreversible ribosomal S6 kinase inhibitor 1/2 inhibitor.

M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

LJI308 is a selective and potent RSK inhibitor.

LJH685 is a selective and potent RSK inhibitor.

BI-D1870 is a small molecule, specific inhibitor of p90 RSK (ribosomal S6 kinase) isoforms RSK1, RSK2, RSK3 and RSK4, both in vitro and in vivo, with IC50s are 31 nM, 24 nM, 18 nM, 15 nM, respectively.

SC1(Pluripotin) is a sustainer of mES self-renewal and ERK 1 inhibitor

RSK4-IN-1 is identified with potent RSK4 inhibitory activity with an IC50 value of 9.5 nM.

Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.

SL 0101-1 is a selective inhibitor of p90 Rsk (ribosomal S6 kinase) (IC50 = 89 nM for Rsk-2).

CMK is a RSK2 kinase inhibitor.